Forest CFC-free inhaler approvable

Published: 30-Jun-2001


Forest Laboratories' asthma treatment Flunisolide HFA has been given an approvable letter by the FDA. The corticosteroid is formulated with a novel hydrofluoroalkane propellant and the device has a built-in spacer. The approvable letter requested further data, and Forest is preparing this in anticipation of a launch at the end of this year or the beginning of next.

  • Companies:
  • Forest Laboratories Inc
See more

You may also like

Finance

Actavis completes US$28bn purchase of Forest Laboratories

Read more
Names new management team

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be complicated. Here, the tablet experts Natoli explain how to develop tabletability, compactibility, and compressibility profiles
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Finance

Actavis completes US$28bn purchase of Forest Laboratories

Names new management team
Finance

Actavis to acquire Forest Laboratories for US$25bn

Creates a company with US$15bn in revenue and a growing $7bn North American speciality brand business
Finance

Forest Pharmaceuticals pleads guilty to violating FDA laws

Company sold unapproved and misbranded drugs and obstructed agency investigation
Finance

Forest and Merz settle Namenda litigation

Generic versions of drug to enter market in 2015
Drug Delivery

Inhalers containing CFCs to be withdrawn in US

Seven metered-dose inhalers to treat asthma and COPD will be phased out

AstraZeneca to acquire Novexel

<p>AstraZeneca is to buy French antibiotics group Novexel for up to US$505m (
Regulatory

Forest Laboratories UK applies for marketing authorisation for dry powder inhalation antibiotic

<p>Forest Laboratories UK (a subsidiary of global pharmaceutical company Forest Laboratories Inc) has applied to the European Medicines Evaluation Agency (EMEA) to license its new formulation dry powder colistimethate sodium for inhalation by cystic fibrosis patients. </p>
Subscribe now